Chronic Lymphocytic Leukemia — Expanded Access Programs
Overview
Right2Hope maintains a directory of 88 expanded access programs, clinical trials, and compassionate use pathways listed for Chronic Lymphocytic Leukemia. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with chronic lymphocytic leukemia programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 47 programs are currently active or recruiting, with the remaining 41 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Acerta Pharma BV, BeiGene, Loxo Oncology, Inc., National Cancer Institute (NCI), and others.
By recruiting status
Snapshot of where every Chronic Lymphocytic Leukemia program currently sits in its lifecycle.
- Active / Recruiting47
- Inactive41
Top sponsors
Organisations running the most Chronic Lymphocytic Leukemia programs in the directory.
- M.D. Anderson Cancer Center7 programs
- Acerta Pharma BV6 programs
- BeiGene6 programs
- Loxo Oncology, Inc.4 programs
- National Cancer Institute (NCI)4 programs
- City of Hope Medical Center3 programs
- Dana-Farber Cancer Institute3 programs
- Eli Lilly and Company3 programs
- Mayo Clinic3 programs
- Merck Sharp & Dohme LLC3 programs
Chronic Lymphocytic Leukemia programs (88)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Long-term Study of Ibrutinib for Ongoing Access and Safety Monitoring — Janssen Research & Development, LLC
- Study on the Long-Term Safety of Pirtobrutinib (LY3527727) — Eli Lilly and Company
- Study on IPI-145 with FCR for Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL) — Dana-Farber Cancer Institute
- Phase II Study of Ibrutinib Plus FCR for Untreated Younger Patients with Chronic Lymphocytic Leukemia — Dana-Farber Cancer Institute
- Phase II Study of Ibrutinib and Short-Course Fludarabine for Untreated Chronic Lymphocytic Leukemia (CLL) — National Heart, Lung, and Blood Institute (NHLBI)
- Study on Bruton Tyrosine Kinase Inhibitor with or without Venetoclax for Veterans with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — VA Office of Research and Development
- Study Comparing Zanubrutinib with Bendamustine and Rituximab for Untreated CLL or SLL — BeiGene
- Study on the Effectiveness and Safety of Pirtobrutinib for Patients with Relapsed or Hard-to-Treat Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Loxo Oncology, Inc.
- Study on Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma — Eli Lilly and Company
- Study Comparing Acalabrutinib with Other Treatments for Previously Treated Chronic Lymphocytic Leukemia (CLL) — Acerta Pharma BV
- Study on Acalabrutinib for Patients with Chronic Lymphocytic Leukemia (CLL) Who Cannot Tolerate Ibrutinib — Acerta Pharma BV
- Study Comparing BGB-16673 with Other Treatments for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — BeiGene
- Study on Emavusertib and a Bruton Tyrosine Kinase Inhibitor for Chronic Lymphocytic Leukemia and Other B-cell Cancers — Curis, Inc.
- Study on Nemtabrutinib for Patients with Difficult-to-Treat Blood Cancers — ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
- Study Comparing Pirtobrutinib (LOXO-305) and Bendamustine Plus Rituximab for Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Loxo Oncology, Inc.
- Study Comparing Pirtobrutinib (LOXO-305) and Ibrutinib for Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Loxo Oncology, Inc.
- Study on Venetoclax and Rituximab/Hyaluronidase for Treating Relapsed or Hard-to-Treat Chronic Lymphocytic Leukemia (CLL) — Georgetown University
- Study on Limiting Treatment Time with Acalabrutinib and Obinutuzumab for People with CLL or SLL — Memorial Sloan Kettering Cancer Center
- Study on the Safety and Effectiveness of BGB-16673 Compared to Pirtobrutinib in Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — BeOne Medicines
- Study on Sonrotoclax with Obinutuzumab or Rituximab Compared to Venetoclax with Rituximab for Treating Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — BeiGene
- Study Comparing Sonrotoclax and Zanubrutinib with Venetoclax and Acalabrutinib in Adults with Untreated Chronic Lymphocytic Leukemia — BeOne Medicines
- Study on the Safety of New Dosing Schedules for Sonrotoclax in Treating Blood Cancers — BeiGene
- Study on Acalabrutinib for Treating Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia — City of Hope Medical Center
- Study on Acalabrutinib, Obinutuzumab, and Chlorambucil for Untreated Chronic Lymphocytic Leukemia (CLL) — Acerta Pharma BV
- Study on Acalabrutinib, Umbralisib, and Ublituximab for Relapsed and Untreated Chronic Lymphocytic Leukemia (CLL) — Jennifer R. Brown, MD, PhD
- Study on Acalabrutinib for Treating Chronic Lymphocytic Leukemia, Richter's Syndrome, or Prolymphocytic Leukemia — Acerta Pharma BV
- Extension Study for Patients Continuing Venetoclax Treatment from Previous Trials — AbbVie
- Study on Bcl-2 Inhibitor GDC-0199 with Obinutuzumab and Ibrutinib for Treating Chronic Lymphocytic Leukemia — Kerry Rogers
- Study on Duvelisib and Venetoclax for Treating Relapsed or Hard-to-Treat CLL, SLL, or Richter's Syndrome — Dana-Farber Cancer Institute
- Study Comparing Ibrutinib and Rituximab with Fludarabine, Cyclophosphamide, and Rituximab for Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — National Cancer Institute (NCI)
- Study Comparing Intermittent and Continuous Venetoclax with Acalabrutinib for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Zulfa Omer
- Study on Lenalidomide and Vaccine Therapy for Early-Stage Asymptomatic Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — National Cancer Institute (NCI)
- Study on LP-168 and Obinutuzumab for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Its Variants — Zulfa Omer
- Study on Mosunetuzumab for Clearing Minimal Residual Disease in Chronic Lymphocytic Leukemia (CLL) — Inhye Ahn
- Study on Nemtabrutinib and Pembrolizumab for Treating Richter Transformation, Diffuse Large B-cell Lymphoma — Roswell Park Cancer Institute
- Phase II Study of Pirtobrutinib, Venetoclax, and Obinutuzumab for Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — M.D. Anderson Cancer Center
- Study on Roginolisib, Venetoclax, and Rituximab for Treating Difficult or Returning Chronic Lymphocytic Leukemia (CLL) — Jennifer R. Brown, MD, PhD
- Study on Ruxolitinib Phosphate for Reducing Fatigue in Patients with Chronic Lymphocytic Leukemia — M.D. Anderson Cancer Center
- Study on the Safety and Effectiveness of KRT-232 with Acalabrutinib for Treating Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia — Kartos Therapeutics, Inc.
- Study on Sonrotoclax, Rituximab, and Zanubrutinib for Treating Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, and Mantle Cell Lymphoma — Fred Hutchinson Cancer Center
- Study on Acalabrutinib and Venetoclax, With or Without Obinutuzumab, Versus Chemoimmunotherapy for Untreated Chronic Lymphocytic Leukemia (CLL) — Acerta Pharma BV
- Study Comparing Acalabrutinib and Ibrutinib for Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) — Acerta Pharma BV
- Study on Epcoritamab as a Follow-Up Treatment for CLL/SLL — Zulfa Omer
- Testing the Addition of Venetoclax to Standard Treatment for Older Patients with Untreated Chronic Lymphocytic Leukemia — National Cancer Institute (NCI)
- Study on Adding Sonrotoclax to Standard Treatment Zanubrutinib for Untreated Chronic Lymphoblastic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Alliance for Clinical Trials in Oncology
- Study on Venetoclax and Obinutuzumab Followed by Epcoritamab for Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma — City of Hope Medical Center
- Study on Zanubrutinib, Obinutuzumab, and Sonrotoclax for Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Massachusetts General Hospital
- Study on BGB-16673 for Patients with B-Cell Blood Cancers — BeiGene
- Phase 2 Study of Glofitamab Alone or with Polatuzumab Vedotin or Atezolizumab for Treating Richter's Transformation — Christine Ryan
- Study Comparing Nemtabrutinib with Ibrutinib or Acalabrutinib for First-Time Treatment of Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) — Merck Sharp & Dohme LLC
- Study Comparing Nemtabrutinib to Chemoimmunotherapy for Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without TP53 Changes — Merck Sharp & Dohme LLC
- Study on Pirtobrutinib for Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Eli Lilly and Company
- Study on Zilovertamab Vedotin as a Single Treatment and in Combination for Aggressive and Slow-Growing B-cell Blood Cancers — Merck Sharp & Dohme LLC
- Study on Adding Venetoclax to Treatment for First-Line Chronic Lymphocytic Leukemia to Achieve Long-Lasting Remissions — Genentech, Inc.
- Study on the Risk of Tumor Lysis Syndrome in Adults Taking Venetoclax with Obinutuzumab or Acalabrutinib for Untreated Chronic Lymphocytic Leukemia — AbbVie
- Study on Sonrotoclax and Zanubrutinib Combination vs. Zanubrutinib Alone for Untreated Chronic Lymphocytic Leukemia — BeiGene
- Study on Using Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adults with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — AstraZeneca
- Study Comparing Pirtobrutinib with Venetoclax and Rituximab to Venetoclax and Rituximab Alone in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Loxo Oncology, Inc.
- Study on Acalabrutinib and Obinutuzumab for Treating Chronic Lymphocytic Leukemia — M.D. Anderson Cancer Center
- Study on Acalabrutinib Combined with Venetoclax or Obinutuzumab for Untreated Chronic Lymphocytic Leukemia — Ohio State University Comprehensive Cancer Center
- Study on Acalabrutinib With or Without Obinutuzumab for Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Mayo Clinic
- Study on Acalabrutinib, Venetoclax, and Durvalumab for Treating Richter Transformation from Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Mayo Clinic
- Study on Atezolizumab, Obinutuzumab, and Venetoclax for Treating Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed/Refractory Richter Syndrome — M.D. Anderson Cancer Center
- Study on Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treating Chronic Lymphocytic Leukemia — Nicole Lamanna
- Study on Cytokine-Treated Veto Cells for Patients with Blood Cancers After Stem Cell Transplant — M.D. Anderson Cancer Center
- Study on Early Genetic Changes During Venetoclax Treatment for Difficult or Returning Chronic Lymphocytic Leukemia (CLL) — National Heart, Lung, and Blood Institute (NHLBI)
- Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia — Inhye Ahn
- Study on Using Donor Blood Stem Cells for Transplant: Focusing on Immune System Checkpoints — Dartmouth-Hitchcock Medical Center
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Post-Transplant Cyclophosphamide — Center for International Blood and Marrow Transplant Research
- Study on HLA-Mismatched Unrelated Donor Stem Cell Transplant with Reduced Cyclophosphamide for Graft Versus Host Disease Prevention — Center for International Blood and Marrow Transplant Research
- Study on Ibrutinib and Vaccine Therapy for Patients with Asymptomatic, High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma — Jennifer Woyach
- Study on Ibrutinib, Fludarabine, and Pembrolizumab for High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — National Heart, Lung, and Blood Institute (NHLBI)
- Local Production of CAR T-Cell Therapy for Treating B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — John Lister
- Study on Metabolically Fit CD19 CAR T-cell Therapy with CD34 Selection for Patients with Difficult or Returning CD19+ Lymphomas and Leukemias — Medical University of South Carolina
- Study on Myeloablative Stem Cell Transplant with Donor for Blood Disorders — Masonic Cancer Center, University of Minnesota
- Phase I/II Study of Rapcabtagene Autoleucel in CLL, Advanced DLBCL, ALL, and High-Risk LBCL — Novartis Pharmaceuticals
- Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients with CLL or SLL Resistant to Covalent BTKi — Kerry Rogers
- Study on Pirtobrutinib (LOXO-305) and Venetoclax for Treating Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — M.D. Anderson Cancer Center
- Study on Pirtobrutinib and Venetoclax with MRD Detection for Untreated Chronic Lymphocytic Leukemia — Mayo Clinic
- Study on Polatuzumab Vedotin with Chemotherapy for Patients with Richter's Transformation — Weill Medical College of Cornell University
- Study on Reduced-Intensity Conditioning to Lower Treatment-Related Deaths in Patients Undergoing Stem Cell Transplant — Thomas Jefferson University
- Study on RP-3500 and Olaparib for Treating Relapsed or Hard-to-Treat Chronic Lymphocytic Leukemia with DNA Repair Issues — University of Utah
- Study of Iopofosine I 131 (CLR 131) for Certain B-Cell Blood Cancers and Waldenstrom Macroglobulinemia — Cellectar Biosciences, Inc.
- Study on the Safety and Early Effectiveness of Ibrutinib and Pembrolizumab in Patients with Chronic Lymphocytic Leukemia (CLL) or Mantle Cell Lymphoma (MCL) — Joshua Brody
- Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study — City of Hope Medical Center
- Testing Early Treatment for Patients with High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study — National Cancer Institute (NCI)
- Study on Venetoclax with Ibrutinib or Acalabrutinib for High-Risk Chronic Lymphocytic Leukemia (CLL) — M.D. Anderson Cancer Center
- Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL — Massachusetts General Hospital
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Chronic Lymphocytic Leukemia to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.